Abelson Murine Leukemia Virus Mutants Deficient in Kinase Activity and Lymphoid Cell Transformation
Overview
Authors
Affiliations
Abelson murine leukemia virus transforms both lymphoid cells and fibroblasts in vitro and induces a unique type of thymus-dependent lymphoma in vivo. Four fibroblast-transforming strains of Abelson murine leukemia virus were identified, based on the sizes of the Abelson murine leukemia virus-specific phosphoproteins produced by these isolates. Two of these strains, the standard P120- and the P160-producing viruses, transformed lymphoid cells efficiently in vitro and induced Abelson disease in vivo. Two other strains, which synthesized small Abelson murine leukemia virus-specific proteins with molecular weights of 90,000 (P90) and 100,000 (P100), transformed lymphoid cells very poorly both in vitro and in vivo. The reduced oncogenic potentials of these isolates were correlated with a high level of synthesis of fairly unstable P90 and P100. In addition, neither P90 nor P100 functional efficiently in protein kinase assays. The correlation of abnormal metabolism and deficient protein kinase activity with the reduced oncogenic potentials of these virus strains supported a direct role for these proteins and the kinase activity in transformation. Furthermore, these results suggested that the requirements for lymphoid cell transformation and fibroblast transformation are different.
Decreased virus population diversity in p53-null mice infected with weakly oncogenic Abelson virus.
Marchlik E, Kalman R, Rosenberg N J Virol. 2005; 79(18):11618-26.
PMID: 16140739 PMC: 1212633. DOI: 10.1128/JVI.79.18.11618-11626.2005.
Warren D, Griffin D, Mainville C, Rosenberg N J Virol. 2003; 77(8):4617-25.
PMID: 12663768 PMC: 152141. DOI: 10.1128/jvi.77.8.4617-4625.2003.
The carboxyl terminus of v-Abl protein can augment SH2 domain function.
Warren D, Heilpern A, Berg K, Rosenberg N J Virol. 2000; 74(10):4495-504.
PMID: 10775585 PMC: 111963. DOI: 10.1128/jvi.74.10.4495-4504.2000.
Inhibition of v-Abl transformation by p53 and p19ARF.
Cong F, Zou X, Hinrichs K, Calame K, Goff S Oncogene. 2000; 18(54):7731-9.
PMID: 10618713 DOI: 10.1038/sj.onc.1203290.
Zou X, Cong F, Coutts M, Cattoretti G, Goff S, Calame K Mol Cell Biol. 1999; 20(2):628-33.
PMID: 10611241 PMC: 85151. DOI: 10.1128/MCB.20.2.628-633.2000.